摘要
目的探讨二甲双胍对长期服抗精神病药物治疗伴肥胖患者体重的影响。方法将长期服抗精神病药物治疗(≥1年)伴肥胖患者120例,随机分为两组各60例,研究组予二甲双胍0.75g/d治疗6个月,对照组不干预直接随访;分别于入组前及入组后1、2、3、6个月测定身高、体重、血压、空腹血糖及入组前和入组后6个月评定PANSS量表。结果 119例完成观察(研究组60例,对照组59例);研究组在入组后1、2、3、6个月时体重减分值、BMI减分值大于对照组,两组差异均有统计学意义(P<0.01)。而空腹血糖减分值在入组后6个月存在统计学差异;入组后3个月研究组BMI与空腹血糖减分值呈正相关;两组PANSS评分差异无统计学意义。结论二甲双胍能有效降低长期抗精神病药物治疗伴肥胖患者的体重。
Objective To investigate the impact of metformin on body weight of psychiatric patients with obesity who have received long - term antipsychotic treatment. Methods 120 subjects with obesity who have received long - term antipsychotic treatment （≥1 year）were randomized into study group （60 subjects） and control group （60 subjects）. Study group received metformin 0. 75 g/day for 6 months, and control group received non - intervention follow - up. The height, weight,blood pressure and fasting glucose were measured at baseline and at the end of 1^st ,2^nd, 3^rd ,6^th month. PANSS were assessed at the baseline and at the end of 6th month. Results 119 patients completed the study （60 patients in study group, 59 patients in control group ）. Weight loss and BMI reducing score in study group were significantly higher than those in control group at the end of 1^st ,2^nd ,3^rd ,6^th month. There was significant difference on fasting blood glucose reducing score at the end of 6^th month between the two groups. There was positive relationship between BMI reducing score and fasting blood glucose reducing score at the end of 6th month in study group. There was no significant difference on PANSS score between the two groups at the baseline and at the end of 6th month. Conclusion Mefformin can reduce body weight of psychiatric patients with obesity who have received long -term antipsychotic treatment.
出处
《精神医学杂志》
2011年第1期5-7,共3页
Journal of Psychiatry
基金
上海市精神卫生中心院级课题项目(编号:2008-15)
上海市卫生局科研课题项目(2009097)
